Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Phase 2 Completed 32 enrolled Chinese Academy of Medical Sciences

NaSingle-groupOpen-labelTreatment

Summary

The hypothesis of this study is to discover if the all-oral therapy with apatinib plus oral Etoposide can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.

Timeline

Start: 2017-05-01
Primary completion: 2019-05-01
Completion: 2019-05-01

Publications

Hu N, Zhu A, Si Y, Yue J, Wang X, Wang J, Ma F, Xu B, Yuan P. A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer. Front Oncol. 2021 Feb 15;10:565384. doi: 10.3389/fonc.2020.565384. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etoposide	Small molecule	50 mg/m2	Oral
Subject	Rivoceranib	Small molecule	425 mg	Oral
Subject	Rivoceranib	Small molecule	500 mg	Oral

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Summary

Timeline

Publications

Drugs

Indications